Medical Advocates
HAART/ART
 
Main Page

New/Noteworthy
Guidelines     
 Children
 Adolescents
 Pregnant Women
 Women
 General Reports 
 Efficacy
 HAART Errors
Drug Interactions 
Adverse Events
 Viral Dynamics
Adherence

Resistance
 Quality-of-Life
 Dosing
 Therapeutic Strategies
 Economics
 Pharmacogenetics
 HIV Transmission
 HIV/HCV Coinfection
 Disease Progression
 Drug Index
Drug Classes
 HAART/ART Failure
HIV Main Page Main New/Newsworthy     Home Page    
This web page is best viewed by using INTERNET EXPLORER
Last Update:  February 04, 2012  
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
 
New and Noteworthy
 
February 2012
 

January 2012
General/Miscellaneous Reports
 

     Journal Papers, Abstracts, and Commentaries

 
Novel agents for the treatment of HIV-2 infection.
Peterson K, Rowland-Jones S.
 Antivir Ther. 2012 Jan 25.
Abstract

Improved Estimation of the Distribution of Suppressed Plasma HIV-1 RNA in Men Receiving Effective
Antiretroviral Therapy.
Schneider MF, Margolick JB, Jacobson LP,  et al
J Acquir Immune Defic Syndr. 2012 Jan
Abstract

The Effect of a 12-Week Course of Omega-3 Polyunsaturated Fatty Acids on Lipid Parameters
in Hypertriglyceridemic Adult HIV-infected Patients Undergoing HAART: A Randomized,
Placebo-Controlled Pilot Trial.
Peters BS, Wierzbicki AS, Moyle G, et al
Clin Ther. 2011 Dec 31.
Abstract

Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials.
 Pichenot M, Deuffic-Burban S, Cuzin L, Yazdanpanah Y.
HIV Med. 2011 Nov 22.
Abstract

Nutrition and disease progression pre-highly active antiretroviral therapy (HAART) and post-HAART:
can good nutrition delay time to HAART and affect response to HAART?
Chandrasekhar A, Gupta A.
Am J Clin Nutr. 2011 Nov 16.
Abstract

Does use of antiretroviral therapy regimens with high central nervous system penetration improve survival in
HIV-infected adults?
McManus H, Li P, Nolan D,  et al
HIV Med. 2011 Aug 7..|
 Abstract

Drug Effectiveness Explained: The Mathematics of Antiviral Agents for HIV.
Perelson AS, Deeks SG.
Sci Transl Med. 2011 Jul 13;3(91):91ps30.
 Abstract

Influence of gender on receipt of guideline-based antiretroviral therapy in the era of HAART.
Cocohoba JM, Althoff KN, Godfrey R, et al
AIDS Care. 2011 Jul 6.
Abstract

Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome
of HIV-1 therapy.
Llibre JM, Arribas JR, Domingo P, et al
AIDS. 2011 Jun 13.
 Abstract

Specific prebiotics modulate gut microbiota and immune activation in HAART-naive
HIV-infected adults: results of the "COPA" pilot randomized trial.
Gori A, Rizzardini G, Van't Land B, et al
Mucosal Immunol. 2011 Apr 27.
 Abstract

Antiretroviral Therapy: A Key Component of a Comprehensive HIV Prevention Strategy.
Hull MW, Montaner J.
 Curr HIV/AIDS Rep. 2011 Mar 29
 Abstract

Lower mortality and earlier start of cART in patients tested repeatedly for HIV than
in those with a positive first test.
Gras L, van Sighem A, Bezemer D,  et al
AIDS. 2011 Feb 16
 Abstract

Indications for the use of next-generation antiretroviral drugs in current clinical practice.
Castillo Romera I, Ais Larisgoitia A, Trovato López AN,  et al
Farm Hosp. 2011 January - February;35(1):14-22..
Abstract

Effect of Gender and Calendar Year on Time to and Duration of Virologic Suppression Among
Antiretroviral-Naïve HIV-Infected Individuals Initiating Combination Antiretroviral Therapy.
Raboud J, Blitz S, Walmsley S, Thompson C,et al
HIV Clin Trials. 2010 Jan 1;11(6):340-350.
 Abstract

A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of
combination antiretroviral therapy is associated with increased mortality in
HIV-infected individuals with viral suppression.
Loutfy MR, Genebat M, Moore D,  et al
J Acquir Immune Defic Syndr. 2010 Dec 1;55(4):451-9.
 Abstract

FULL-TEXT ARTICLE
 Therapeutic Immunization with HIV-1 Tat Reduces Immune Activation and
Loss of Regulatory T-Cells and Improves Immune Function in Subjects on HAART.
Ensoli B, Bellino S, Tripiciano A,  et al
PLoS One. 2010 Nov 11;5(11):e13540.
 Paper

Responses to highly active antiretroviral therapy and clinical events in patients with a
low CD4 cell count: late presenters vs. late starters.
Waters L, Fisher M, Anderson J, et a
HIV Med. 2010 Nov 3.
Abstract

Antiretroviral treatment 2010: progress and controversies.
Gulick RM.
 J Acquir Immune Defic Syndr. 2010 Dec 1;55 Suppl 1:S43-8.
 Abstract

Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly
low levels of HIV reservoir: implications for eradication.
Chun TW, Justement JS, Murray D, et al
AIDS. 2010 Oct 19
 Abstract

Role of fixed-dose combinations of antiretrovirals in HIV-1 therapy.
 Llibre JM, Antela A, Arribas JR,  et al
Enferm Infecc Microbiol Clin. 2010 Sep 29
 Abstract

Novel antiretroviral combinations in treatment-experienced patients with HIV infection:
rationale and results.
Taiwo B, Murphy RL, Katlama C.
Drugs. 2010 Sep 10;70(13):1629-42.
Abstract

Harmful alcohol consumption and patterns of substance use in HIV-infected patients
receiving antiretrovirals (ANRS-EN12-VESPA Study): relevance for clinical management
and intervention.
Michel L, Carrieri MP, Fugon L,  et al
AIDS Care. 2010 Sep;22(9):1136-1145.
 Abstract

Virologic and immunologic response to HAART, by age and regimen class.
Althoff KN, Justice AC, Gange SJ,  et al
AIDS. 2010 Sep 8
 Abstract

Prediction of response to antiretroviral therapy by human experts and by the EuResist
data-driven expert system (the EVE study)
 Zazzi M, Kaiser R, Sönnerborg A,  et al
HIV Med. 2010 Aug 19
 Abstract

Antiretroviral therapy and management of HIV infection.
Volberding PA, Deeks SG
 Lancet. 2010 Jul 3;376(9734):49-62
 Abstract

Obstacles and Opportunities to Improve Antiretroviral Regimen Access in
Low-Income Countries.
Cohn J, Baker B.
Curr HIV/AIDS Rep. 2010 Jun 8
 Abstract

Antiretroviral drugs.
De Clercq E.
Curr Opin Pharmacol. 2010 May 12.
 Abstract

The future of antiretroviral therapy: challenges and needs.
Moreno S, López Aldeguer J, Arribas JR, et al
J Antimicrob Chemother. 2010 Mar 12
 Abstract

Treatment modification in human immunodeficiency virus-infected individuals starting
combination antiretroviral therapy between 2005 and 2008.
Elzi L, Marzolini C, Furrer H, Ledergerber B, et al
Arch Intern Med. 2010 Jan 11;170(1):57-65.
 Abstract

Prognosis of patients treated with cART from 36 months after initiation, according to current
and previous CD4 cell count and plasma HIV-1 RNA measurements.
The antiretroviral therapy cohort collaboration (ART-CC)
AIDS. 2009 Sep 23.
Abstract

Early mortality and cause of deaths in patients using HAART in Brazil and the United States.
Grinsztejn B, Veloso VG, Friedman RK,  et al 
AIDS. 2009 Sep 16.
 Abstract

Evolution of the incidence and aetiology of fever of unknown origin (FUO), and survival in
HIV-infected patients after HAART (Highly Active Antiretroviral Therapy).
Abellán-Martínez J, Guerra-Vales JM, Fernández-Cotarelo MJ, González-Alegre MT.
 Eur J Intern Med. 2009 Sep;20(5):474-7.
Abstract

Treatment during Primary HIV Infection Does Not Lower Viral Set Point
but Improves CD4 Lymphocytes in an Observational Cohort.
Koegl C, Wolf E, Hanhoff N, Jessen
Eur J Med Res. 2009 Jul 22;14(7):277-83
 Abstract

Higher risk of AIDS or death in patients with lower CD4 cell counts after virally
suppressive HAART.
Taiwo B, Li X, Palella F, et al 
HIV Med. 2009 Jul 9.
Abstract

HIV/AIDS: Recent Advances in Antiretroviral Agents.
Nikolopoulos G, Bonovas S, Tsantes A, Sitaras NM.
 Mini Rev Med Chem. 2009 Jul;9(8):900-10.
 Abstract

The relationship between genotypic sensitivity score and treatment outcomes in late stage
HIV disease after supervised HAART.
Castor D, Vlahov D, Hoover DR, et al
J Med Virol. 2009 Jun 23;81(8):1323-1335
 Abstract

Newer antiretroviral agents and how to use them.
Kim HH, Daar ES.
 Curr Infect Dis Rep. 2009 Jul;11(4):327-34.
 Abstract

Improvements in antiretroviral therapy outcomes over calendar time.
Boyd MA.
 Curr Opin HIV AIDS. 2009 May;4(3):194-9.
 Abstract

FULL-TEXT PDF ARTICLE
 Advances in antiretroviral therapy.
Wilkin TJ, Taylor B, Olender S, Hammer SM.
Top HIV Med. 2009 Apr-May;17(2):68-88.
 Paper

FULL-TEXT PDF ARTICLE
 Complications of HIV Disease and Antiretroviral Therapy.
 Currier JS, Havlir DV.
 Top HIV Med. 2009 Apr-May;17(2):57-67.
 Paper

Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of
experience in routine clinical practice.
Fabbiani M, Di Giambenedetto S, Bracciale L, et al 
J Antimicrob Chemother. 2009 Apr 27.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Newer antiretroviral agents and how to use them.
Kim HH, Daar ES.
Curr HIV/AIDS Rep. 2009 May;6(2):55-62
 Abstract
 
Inverse probability-of-censoring weights for the correction of time-varying noncompliance in the effect of
randomized highly active antiretroviral therapy on incident AIDS or death.
Cain LE, Cole SR.
 Stat Med. 2009 Apr 3
 Abstract
 
Antiretroviral therapy in human immunodeficiency virus infection: An update.
Chaix F, Goujard C.
Rev Med Interne. 2009 Feb 21
 Abstract
 
Pharmaceutical approaches to eradication of persistent HIV infection.
Bowman MC, Archin NM, Margolis DM.
 Expert Rev Mol Med. 2009 Feb 11;11:e6.
 Abstract
 
Boosted Protease Inhibitor-Based or Nonnucleoside Reverse Transcriptase-Based HAART:
Is There a Best Choice for Antiretroviral-Naive HIV-1 Infected Patients?
Cuzin L, Allavena C, Morlat P, Dellamonica P.
 AIDS Rev. 2008 Oct-Dec;10(4):205-11.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 The Therapeutic Implications of Timely Linkage and Early Retention in HIV Care.
Ulett KB, Willig JH, Lin HY, et al
AIDS Patient Care STDS. 2008 Dec 4.
Abstract
 
Major reduction in AIDS-mortality inequalities after HAART: The importance of absolute
differences in evaluating interventions.
Regidor E, Sánchez E, de la Fuente L, et al
Soc Sci Med. 2008 Dec 2
 Abstract
 
Effect of age and HAART regimen on clinical response in an urban cohort of HIV-infected
individuals.
Greenbaum AH, Wilson LE, Keruly JC, et al
AIDS. 2008 Nov 12;22(17):2331-9
 Abstract
 
Mortality and loss to follow-up among HAART initiators in rural South Africa.
Macpherson P, Moshabela M, Martinson N, Pronyk P.
Trans R Soc Trop Med Hyg. 2008 Nov 12
 Abstract
 
Rational use of modern substances for the treatment of HIV-infection.
Rockstroh JK, Wasmuth JC.  
Internist (Berl). 2008 Oct 24.
 Abstract
 
Better CD4+ T cell recovery in Brazilian HIV-infected individuals under HAART due to cumulative
carriage of SDF-1-3'A, CCR2-V64I, CCR5-D32 and CCR5-promoter 59029A/G polymorphisms.
Rigato PO, Hong MA, Casseb J, et a
Curr HIV Res. 2008 Sep;6(5):466-73
 Abstract
 
CD4(+) T Cell Count Recovery in HIV Type 1-Infected Patients Is Independent of Class of
Antiretroviral Therapy.
Khanna N, Opravil M, Furrer H, et al
Clin Infect Dis. 2008 Sep 10.
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Genetic factors that confer sensitivity to HAART in HIV-infected subjects: implication of
a benefit of an earlier initiation of HAART.
Nakajima T, Kimura A.
Pharmacogenomics. 2008 Sep;9(9):1347-1351.
 Abstract
 
Current use of antiretroviral treatment.
Bailey AC, Fisher M.
Br Med Bull. 2008 Aug 29.
Abstract
 
Stimulant use is associated with immune activation and depleted tryptophan among HIV-positive persons
on anti-retroviral therapy.
Carrico AW, Johnson MO, Morin SF, et al
Brain Behav Immun. 2008 Aug 3.
 Abstract
 
FULL TEXT PDF ARTICLE
Advances in antiretroviral therapy.
 Wilkin TJ, Taylor B, Olender S, Hammer SM.
Top HIV Med. 2008 Mar-Apr;16(1):31-60.
 Paper
 
Poor Initial CD4+ Recovery With Antiretroviral Therapy Prolongs Immune Depletion and Increases Risk
for AIDS and Non-AIDS Diseases.
Baker JV, Peng G, Rapkin J, et al
 J Acquir Immune Defic Syndr. 2008 Jul 12.
 Abstract
 
Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from
structured treatment interruptions.
Eron JJ.
J Infect Dis. 2008 May 15;197
Abstract
 
Effects of antiretroviral therapy on cognitive impairment.
Liner Ii KJ, Hall CD, Robertson KR.
 Curr HIV/AIDS Rep. 2008 May;5(2):64-71
 Abstract
 
Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives.
 El-Ibiary SY, Cocohoba JM. 
Eur J Contracept Reprod Health Care. 2008 Jun;13(2):123-32.
 Abstract
 
Does Antiretroviral Therapy Prevent HIV Transmission to Sexual Partners?
Lalani T, Hicks C.z
Curr Infect Dis Rep. 2008 May;10(2):140-5.
 Abstract
 
Immunological rebound after initiation of highly active antiretroviral therapy in
treatment-naive patients.
Blackard JT, Welles SL, Ackerman A, et al
A  IDS Res Hum Retroviruses. 2008 Mar;24(3):499-504.
Abstract
 
A WEEK IN REVIEW FEATURED REPORT
 FULL TEXT PDF ARTICLE
 Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral
therapy.
Palmer S, Maldarelli F, Wiegand A, et al 
Proc Natl Acad Sci U S A. 2008 Mar 10
Paper
 
Antiretroviral therapy: Principles for treating HIV infection.
Launay O.
Presse Med. 2008 Feb 29
 Abstract
 
New approaches to the treatment of the HIV-infected patient
Chandrika K, Dellot P, Frippiat F, et al  
Rev Med Liege. 2007;62 Spec No:47-50.
 Abstract
 
Part XV. antiretroviral therapy for human immunodeficiency virus infection.
Stephens JR, Rathbun RC, Lockhart SM, et al
J Okla State Med Assoc. 2007 Nov;100(11):417-24
 Abstract
 
The safety of antiretroviral drugs.
 Tymchuk CN, Currier JS. 
Expert Opin Drug Saf. 2008 Jan;7(1):1-4.
 Abstract
 
Unmeasured confounding caused slightly better response to HAART within than
outside a randomized controlled trial.
 Eg Hansen AB, Gerstoft J, Kirk O, et al 
J Clin Epidemiol. 2008 Jan;61(1):87-94.
 Abstract
 
Changes in Outcome of Persons Initiating Highly Active Antiretroviral Therapy at a CD4
Count Less Than 50 Cells/mm3.
 Porter K, Walker S, Hill T, Anderson J, et al
 J Acquir Immune Defic Syndr. 2007 Oct 25;
 Abstract
 
The Influence of Psychosocial Characteristics and Race/Ethnicity on the Use, Duration,
and Success of Antiretroviral Therapy.
 Pence BW, Ostermann J, Kumar V, et al
 J Acquir Immune Defic Syndr. 2007 Oct 25;
Abstract
 
Late diagnosis of HIV infection: epidemiological features, consequences and strategies to
encourage earlier testing
 Girardi E, Sabin CA, Monforte AD, et al
J Acquir Immune Defic Syndr. 2007 Sep;46 Suppl 1:S3-8.
Abstract
 
Patient preferences among third agent HIV medications: a US and German perspective.
 Beusterien KM, Dziekan K, Schrader S, et al 
AIDS Care. 2007 Sep;19(8):982-8.
 Abstract
 
Pharmacokinetics and pharmacodynamics in HAART and antibiotic therapy.
Boffito M 
New Microbiol. 2007 Jul;30(3):346-9.
 Abstract
 
Successful HAART Is Associated with High B-Chemokine Levels in Chronic HIV Type
1-Infected Patients.
Brito A, Almeida A, Gonsalez CR. et al
AIDS Res Hum Retroviruses. 2007 Jul;23(7):906-12.
 Abstract
 
Continuous evidence of fast HIV disease progression related to class-wide resistance to
antiretroviral drugs: a 6 year follow-up analysis of a large observational database.
Mauro Z, Federica F, Patrizia L, et al
AIDS. 2007 Aug 20;21(13):1824-1826.
 Abstract
 
Impact of Ethnicity and HIV Type 1 Subtype on Response to First-Line Antiretroviral Therapy.
[Spain]
De Arellano ER, Benito JM, Soriano V, et al
 AIDS Res Hum Retroviruses. 2007 Jul;23(7):891-4.
 Abstract
 
A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy
in HIV-1 infected men.
 May M, Sterne JA, Shipley M, et al
Int J Epidemiol. 2007 Jul 25;
 Abstract
 
The Antiretroviral Regimen Complexity Index: A Novel Method of Quantifying Regimen
Complexity.
Martin S, Wolters PL, Calabrese SK, et al 
J Acquir Immune Defic Syndr. 2007 Jun 21;
Abstract
 
Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a
prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384.
 Dubé MP, Parker RA, Mulligan K, et al
 Clin Infect Dis. 2007 Jul 1;45(1):120-6.
 Abstract
 
FULL TEXT PDF ARTICLE
Advances in HIV Therapy
 Jones J, Taylor B, Wilkin TJ, Hammer SM.
Top HIV Med. 2007 Apr-May;15(2):48-82.
 Paper
 
Chronic HIV infection : Current therapeutic aspects.
Vogel M, Rockstroh JK
Internist (Berl). 2007 Apr 13;
 Abstract
 
Ten years of highly active antiretroviral therapy for HIV infection.
 Chen LF, Hoy J, Lewin SR.
 Med J Aust. 2007 Feb 5;186(3):146-51.
 Abstract
 
FULL TEXT ARTICLE
 Access to generic antiretrovirals: inequality, intellectual property law, and international
trade agreements.
 Castro A, Westerhaus M
 Cad Saude Publica. 2007 00;23:S85-S96.
Paper
 
Discordant immunological and virological responses to antiretroviral therapy.
 Schechter M, Tuboi SH.
Antimicrob Chemother. 2006 Jul 19;
 Abstract
 
Effect of Baseline- and Treatment-Related Factors on Immunologic Recovery After Initiation of
Antiretroviral Therapy in HIV-1-Positive Subjects: Results From ACTG 384.
 Gandhi RT, Spritzler J, Chan E,et al  
J Acquir Immune Defic Syndr. 2006 Jun 26;
 Abstract
 
Seroreversion in Subjects Receiving Antiretroviral Therapy during Acute/Early HIV Infection.
Hare CB, Pappalardo BL, Busch MP, Karlsson AC, et al 
Clin Infect Dis. 2006 Mar 1;42(5):700-8.
Abstract
 
Disease progression in patients with virological suppression in response to HAART
is associated with the degree of immunological response.
Moore DM, Hogg RS, Chan K, et al
 AIDS. 2006 Feb 14;20(3):371-7.
Abstract
 
Determinants of response to first HAART regimen in antiretroviral-naive patients with an
estimated time since HIV seroconversion.
Thiebaut R, Jacqmin-Gadda H, Walker S, et al 
HIV Med. 2006 Jan;7(1):1-9.
 Abstract
 
FULL TEXT ARTICLE
 HIV-infected individuals receiving effective antiviral therapy for extended periods of time
continually replenish their viral reservoir.
Chun TW, Nickle DC, Justement JS, et al
J Clin Invest. 2005 Nov 1;115(11):3250-3255.
Paper
 
Antiretroviral therapy: an update for the non-AIDS specialist.
Kalkut G.
Curr Opin Oncol. 2005 Sep;17(5):479-84
Abstract
 
Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete
virologic or immunologic response to HAART.
Nicastri E, Chiesi A, Angeletti C, Sarmati L, et al 
J Med Virol. 2005 Apr 15;76(2):153-16
 Abstract
 
Impact of highly active antiretroviral therapy on organ-specific manifestations of
HIV-1 infection.
Torre D, Speranza F, Martegani R.
HIV Med. 2005 Mar;6(2):66-78.
 Abstract
 
FULL TEXT ARTICLE
 Treatment exhaustion of highly active antiretroviral therapy (HAART) among
individuals infected with HIV in the United Kingdom: multicentre cohort study
 Sabin CA,  Hill T, Lampe F, et al
BMJ  2005;330:695 (26 March)
 Paper
 
Why are Baseline HIV RNA Levels 100,000 Copies/mL or Greater Associated With
Mortality After the Initiation of Antiretroviral Therapy?
Wood E, Hogg RS, Yip B, Harrigan PR, Montaner JS.
J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):289-295
 Abstract
 
Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.
Nettles RE, Kieffer TL, Kwon P,
JAMA. 2005 Feb 16;293(7):817-29.
 Abstract
 
Late presenters in the era of highly active antiretroviral therapy: uptake of
and responses to antiretroviral therapy.
Sabin CA, Smith CJ, Gumley H, Murphy G, et al
AIDS. 2004 Nov 5;18(16):2145-51
 Abstract
 
Long-Term Follow-Up of HIV-Infected Individuals Who Have Significant Increases in
CD4+ Cell Counts during Antiretroviral Therapy.
Koletar SL, Williams PL, Wu J, et al 
Clin Infect Dis. 2004 Nov 15;39(10):1500-6.
 Abstract
 
FULL TEXT ARTICLE
 Limited Durability of Viral Control following Treated Acute HIV Infection
Kaufmann DE,  Lichterfeld M, Altfeld, M, et al
PLoS Medicine Vol 1, No 2
 Paper
 
HIV update: emerging clinical evidence and a review of recommendations for the
use of highly active antiretroviral therapy.
Kress KD.
Am J Health Syst Pharm. 2004 Oct 1;61 Suppl 3:S3-14
 Abstract
 
Pharmacologic Perspectives for Once-Daily Antiretroviral Therapy (CE) (November).
Anderson PL
Ann Pharmacother. 2004 Oct 12
Abstract
 
A significant proportion of HIV-infected patients admitted to hospital have
immunosuppression as a result of failure of highly active antiretroviral therapy.
Manavi K, McMillan A.
HIV Med. 2004 Sep;5(5):360-3.
 Abstract
 

     Conference Reports, Abstracts, and Posters

 
Cumulative viremia under HAART predicts long-term clinical outcomes
V.D. Lima, J. Sierra-Madero, Z. Wu, et al
 (18 CROI)
 Abstract

15 Years of HAART: What Does the Future Hold?
P Yeni
(18 CROI)
 Abstract

POSTER
 Role of Baseline CD4 and Viral Load in CD4 Increase in Patients Initiating HAART
with CD4< 200 Cells/muL
E Ferrer, J Curto, A Esteve,  et al
 (17th CROI)
 PDF Poster     Abstract
 

POSTER
 CD4 at HAART Initiation Predicts Long-term CD4 Responses and Mortality from AIDS and Non-
AIDS Causes in the HIV Outpatient Study
F Palella, C Armon, K Buchacz, et al
 (17th CROI)
PDF Poster     Abstract

POSTER
 Non-AIDS-defining Events among HAART-treated Adults in an Urban US vs an Urban
Sub-Saharan African Setting
W Wester, B Shepherd, H Hong, et al
 (17th CROI)
 PDF Poster    Abstract
 
Association between Low-level Viremia below 50 Copies/mL and Risk of Virologic Rebound i
n HIV-infected Patients Receiving HAART
AM Geretti, T Doyle, C Smith, et al
 (17th CROI)
 Abstract

POSTER
 Impact of generic HAART and free rollout programs on time to initiation of HAART in developing
settings: findings from a tertiary center in Chennai, India
S.S. Solomon, S.H. Mehta, N. Kumarasamy, et al
 (5th IAS Conference)
PDF Poster     Abstract

POSTER
 Natural Killer Cell and CD8+ T Cell Responses to TLR Agonists in HIV-1+ Individuals Receiving
HAART
 A Coleman, M Bowe, B Wahren, et al
 (16 CROI)
 PDF Poster     Abstract

POSTER
 Stability of HIV Reservoir Resting CD4 T Cell Subsets under Effective HAART
V Avettand-Fenoel, B Descours, L Hocqueloux, et al
 (16 CROI)
 PDF Poster     Abstract
 
POSTER
 Differences in Risk Factors for Early and Late Losses to Follow-up in a Public HAART Clinic in
outh Africa
P Majuba, D Westreich M Maskew, et al
(16 CROI)
PDF Poster     Abstract
 
Reasons for Hospitalization that Occurs after HAART Initiation
S Berry, Y Manabe, R Moore,  K Gebo
(16 CROI)
 Abstract
 
Peripheral Blood and Gut T Cell Cycling Appear to Be Regulated Independently but
Both Are Substantially
Reduced by HAART
E Ciccone, S Read, P Mannon, et al
(16 CROI)
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
How will we use the new ART drugs?
C Katlama
 (Ninth International Congress on Drug Therapy in HIV Infection)
 PDF Abstract
 
POWERPOINT POSTER PRESENTATION
Risk factors for tuberculosis within 3 months of HAART initiation
T Sterling
(XVII International AIDS Conference)
 Poster Presentation
 
Dietary intervention when starting HAART prevents the increase in lipids independently
of drug regimen: a randomized trial
 Lazzaretti R, Pinto-Ribeiro J, Kummer R, et al
 (4th IAS Conference)
 Abstract
 
Measurement of pretreatment peripheral blood naïve CD4+ T cell percent (nCD4%): a nomogram for
predicting CD4 increase on antiretroviral therapy (ART)
 Schacker T, Bosch R, Bennett K, et al
 (4th IAS Conference)
 Abstract
 
Genotypic sensitivity score predicts successful treatment outcomes after supervised
HAART in late stage HIV disease
 Castor D, Vlahov D, Hoover D, et al
 (4th IAS Conference)
 Abstract
 
Naïve CD4+ T cell homeostasis during HIV infection
 Rickabaugh TM, Kilpatrick R, Fauce SR, et al
 (4th IAS Conference)
 Abstract
 
Functional study of peripheral blood dendritic cells isolated from HIV infected patients before
and after HAART
 Klangsinsirikul P, Dettrairat S, Leechanachai P
 (4th IAS Conference)
 Abstract
 
Gender-based differences in HIV treatment and outcome among patients receiving
generic HAART in South India
 Kumarasamy N, Venkatesh K, Cecelia A. et al
 (4th IAS Conference)
 Abstract
 
Expanded access to HAART: A powerful strategy to curb the growth of the HIV epidemic
and costs
 Lima VD, Johnson K, Hogg RS, et al
 (4th IAS Conference)
 Abstract
 
POSTER
 Partial Normalization of the Activated Immune Response in Lymph Nodes of
HIV-infected Individuals Under ART
S Ehrhard, M Wernl, M Battegay, et al
 (13 CROI)
PDF Poster     Abstract
 
POSTER
 Central Nervous System Immune Activation Is Still Present after More than 4 Years of
Effective HAART
 A Edén, R Price, S Spudich, D Fuchs
(13 CROI)
 PDF Poster     Abstract
Efficacy Studies (also see specific Drug Studies)
       
     Journal Papers, Abstracts, and Commentaries
 
 
Effects of highly active antiretroviral therapy on cognitive functions in severely immune-compromised
HIV-seropositive patients.
Obiabo YO, Ogunrin OA, Ogun AS.
J Neurol Sci. 2011 Oct 11.
 Abstract

FULL-TEXT ARTICLE
 Does HAART efficacy translate to effectiveness? Evidence for a trial effect.
Menezes P, Miller WC, Wohl DA, et al
PLoS One. 2011;6(7):e21824.
 Paper

Factors associated with virological suppression among HIV-positive individuals on
highly active antiretroviral therapy in a multi-site Canadian cohort.
Cescon A, Cooper C, Chan K, et al
HIV Med. 2010 Nov 8
 Abstract

Long-term increase in CD4+ T-cell counts during combination antiretroviral
therapy for HIV-1 infection.
Lok JJ, Bosch RJ, Benson CA, et al  
 AIDS. 2010 May 12.
 Abstract

Therapeutic effect and safety evaluation on 6-year highly active antiretroviral therapy
for Chinese HIV-1 infected patients.
Zhou H, Zheng Y, He Y, et al
 Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2009 Aug;34(8):731-737.
 Abstract

Medium-Term Probability of Success of Antiretroviral Treatment after Early Warning
Signs of Treatment Failure in West African Adults.
Danel C, Gabillard D, Inwoley A, et al
AIDS Res Hum Retroviruses. 2009 Jul 20
 Abstract

Sub-optimal CD4 recovery on long-term suppressive highly active antiretroviral therapy is associated
with favourable outcome.
Onen NF, Overton ET, Presti R, et al
HIV Med. 2009 May 6.
 Abstract

HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness
and illicit drug use.
Chander G, Himelhoch S, Fleishman JA, et al 
AIDS Care. 2009 May;21(5):655-63.
 Abstract

Time taken to undetectable viral load, following the initiation of HAART.
Currie S, Rogstad KE, Piyadigamage A, Herman S.
Int J STD AIDS. 2009 Apr;20(4):265-6.
 Abstract
 
Incomplete Reconstitution of T Cell Subsets on Combination Antiretroviral Therapy in the
AIDS Clinical Trials Group Protocol 384.
Robbins GK, Spritzler JG, Chan ES, et al 
Clin Infect Dis. 2009 Jan 5
 Abstract
 
The Absence of CD4(+) T Cell Count Recovery Despite Receipt of Virologically Suppressive Highly
Active Antiretroviral Therapy: Clinical Risk, Immunological Gaps, and Therapeutic Options.
Gazzola L, Tincati C, Bellistrì GM, et al
 Clin Infect Dis. 2009 Jan 5
 Abstract
 
Art therapy for relief of symptoms associated with HIV/AIDS.
Rao D, Nainis N, Williams L, et al
AIDS Care. 2009 Jan;21(1):64-9.
 Abstract
 
Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy.
Willig JH, Abroms S, Westfall AO, et al
AIDS. 2008 Oct 1;22(15):1951-1960.
Abstract
 
Antiretroviral therapy and central nervous system HIV type 1 infection.
Price RW, Spudich S.  J
  nfect Dis. 2008 May 15;197 Suppl 3:S294-306.
 Abstract
 
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART
at baseline in the SMART study.
Strategies for Management of Antiretroviral Therapy (SMART) Study Group
 J Infect Dis. 2008 Apr 15;197(8):1133-44.
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Efficacy and Safety of Once-Daily Regimens in the Treatment of HIV Infection.
Molina JM.
Drugs. 2008;68(5):567-78.
 Abstract
 
Differential improvement in survival among patients with AIDS after the introduction of HAART.
Couzigou C, Semaille C, Strat YL, et al
AIDS Care. 2007 Apr;19(4):523-31.
 Abstract
Continued improvement in survival among HIV-infected individuals with newer forms of highly
active antiretroviral therapy.
Lima VD, Hogg RS, Harrigan PR, et al
AIDS. 2007 Mar 30;21(6):685-692.
Abstract
 
CD4 Cell Counts of 800 Cells/mm3or Greater After 7 Years of Highly Active Antiretroviral
Therapy Are Feasible in Most Patients Starting With 350 Cells/mm3 or Greater.
Gras L, Kesselring AM, Griffin JT, et al
J Acquir Immune Defic Syndr. 2007 Mar 29;
 Abstract
 
FULL-TEXT ARTICLE
 Clinical Outcome of HIV-Infected Patients with Sustained Virologic Response to
Antiretroviral Therapy: Long-Term Follow-Up of a Multicenter Cohort.
Gutierrez F, Padilla S, Masia M, et al 
PLoS ONE. 2006 Dec 20;1(1):e89.
 Paper
 
Pretreatment Factors Associated With 3-Year (144-Week) Virologic and Immunologic
Responses to Potent Antiretroviral Therapy.
Bosch RJ, Bennett K, Collier AC, et al 
J Acquir Immune Defic Syndr. 2006 Nov 30;
Abstract
 
Follow up of HIV-infected patients under antiretroviral treatment
Chirouze C, Hoen B. 
Rev Prat. 2006 May 15;56(9):966-75.
Abstract
 
Clinical trial comparing efficacy and safety of four highly active antiretroviral therapy (HAART) in
antiretroviral-naive treatment with advanced HIV infection.
Geijo Martinez MP, Macia Martinez MA, Solera Santos J, et al
Rev Clin Esp. 2006 Feb;206(2):67-76.
 Abstract
 
Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death:
a prospective cohort study.
Sterne JA, Hernan MA, Ledergerber B,  et al
Lancet. 2005 Jul 30-Aug 6;366(9483):378-84.
Abstract
 
Response to Highly Active Antiretroviral Therapy at 6 Months and Long-Term Disease
Progression in HIV-1 Infection.
 Grabar S, Moing VL, Goujard C
J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):284-292.
 Abstract
 
     Conference Reports, Abstracts, and Posters  
 
 
POSTER
 Improved Neuropsychological Function during HAART in Diverse Resource-limited Settings: AIDS Clinical Trials
Group Study A5199, the International Neurological Study
K Robertson, H Jiang, S Tripathy, et al
(16 CROI)
 PDF Poster     Abstract
 

Immune restoration during HAART: 8-year follow-up in HIV-positive patients with sustained
virological suppression
Malincarne L, Sgrelli A, Camanni G, et al
(Ninth International Congress on Drug Therapy in HIV Infection)
 Abstract
HAART Errors
       
     Journal Papers, Abstracts, and Commentaries
 
 
Antiretroviral Medication Errors among Hospitalized Patients with HIV Infection.
Rastegar DA, Knight AM, Monolakis JS. 
Clin Infect Dis. 2006 Oct 1;43(7):933-8.
Abstract
 
Medication Error in the Care of HIV/AIDS Patients: Electronic Surveillance,
Confirmation, and Adverse Events.
Delorenze GN, Follansbee SF, Nguyen DP, et al 
Med Care. 2005 Sep;43(9 suppl):63-68.
 Abstract

Inappropriate Drug Combinations Among Privately Insured Patients With
HIV Disease.
Hellinger FJ, Encinosa WE.
Med Care. 2005 Sep;43(9 Suppl):53-62.
Abstract
Disease Progression on HAART
       
     Journal Papers, Abstracts, and Commentaries
 
 
The effect of depressive symptoms at ART initiation on HIV clinical progression and mortality:
implications in clinical practice.
Villes V, Spire B, Lewden C, Perronne C,et al 
Antivir Ther. 2007;12(7):1067-74.
Abstract
 
Absolute Count and Percentage of CD4+ Lymphocytes Are Independent Predictors of
Disease Progression in HIV-Infected Persons Initiating Highly Active Antiretroviral Therapy.
Hulgan T, Shepherd BE, Raffanti SP, et al 
J Infect Dis. 2007 Feb 1;195(3):425-31.
Abstract

Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting
highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
Bonnet F, Thiebaut R, Chene G, et al 
HIV Med. 2005 May;6(3):198-205.5.
Abstract

Rates of Disease Progression among Human Immunodeficiency Virus-Infected
Persons Initiating Multiple-Drug Rescue Therapy.
 Lee N, Hogg RS, Yip B, et al
Abstract

     Conference Reports, Abstracts, and Posters  

 
A CD4 threshold below 350 cells/mm3 for starting HAART is associated with a higher risk
of disease progression
 van Sighem A, Gras L, Smit C, et al
 (4th IAS Conference)
 Abstract

POSTER
 Predictive Indicators of Disease Progression in HAART-treated Patients with HIV-related
Leukoencephalopathies
S Delbue, M Saresella, E Marchioni, et al
 (13 CROI)
 PDF Poster     Abstract
Quality of Life
 
      Journal Papers, Abstracts, and Commentaries
 
 
Racial differences in changes of metabolic parameters and body composition in antiretroviral therapy-naive
persons initiating antiretroviral therapy.
 Gibert CL, Shlay JC, Sharma S, et al
 J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):44-53.
 Abstract
 
Mild-to-Moderate Symptoms during the First Year of Antiretroviral Therapy Worsen
Quality of Lifein HIV-Infected Individuals.
 Mannheimer SB, Wold N, Gardner EM, et al
Clin Infect Dis. 2008 Feb 15
Abstract
 
Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral
therapy (HAART): a balancing act.
 Burgoyne RW, Tan DH.
J Antimicrob Chemother. 2008 Jan 3
Abstract
 
Adverse quality of life consequences of antiretroviral medications.
Park-Wyllie LY, Strike CS, Antoniou T, Bayoumi AM.
AIDS Care. 2007 Feb;19(2):252-7.
 Abstract
 
Impacts of HIV infection and HAART use on quality of life.
Liu C, Ostrow D, Detels R, et aL
 Qual Life Res. 2006 Aug;15(6):941-9.
 Abstract
 
FULL-TEXT PDF ARTICLE
Assessing the effect of HAART on quality of life among HIV-infected women.
Liu C, Weber K, Robison E, Hu Z, et al
AIDS Res Ther. 2006 Mar 20;3(1):6
Paper
 
Better quality of life with neuropsychological improvement on HAART.
Parsons TD, Braaten AJ, Hall CD, Robertson KR.
Health Qual Life Outcomes. 2006 Feb 24;4(1):11
Abstract
 
Beyond efficacy: the impact of combination antiretroviral therapy on quality of life.
Sax PE, Gathe JC.
AIDS Patient Care STDS. 2005 Sep;19(9):563-76.
Abstract

Long-Term Quality-of-Life Outcomes Among Adults Living with HIV in the
HAART Era: The Interplay of Changes in Clinical Factors and Symptom Profile.
 Burgoyne RW, Rourke SB, Behrens DM, Salit IE. 
AIDS Behav. 2004 Jun;8(2):151-63
 Abstract
 
     Conference Reports, Abstracts, and Posters
 
  Quality of life of HIV-infected individuals in a community-based antiretroviral programme
Pitt J, Myer L, Wood R
 (Ninth International Congress on Drug Therapy in HIV Infection)
 Abstract
Dosing
       
     Journal Papers, Abstracts, and Commentaries
 
 
Antiretroviral drug dosing errors in HIV-infected patients undergoing hemodialysis.
 Tourret J, Tostivint I, Tézenas Du Montcel S, et al
Clin Infect Dis. 2007 Sep 15;45(6):779-84.
Abstract

Repeated measures analyses of dose timing of antiretroviral medication and its
relationship to HIV virologic outcomes.
Liu H, Miller LG, Golin CE, et al
Stat Med. 2006 Jun 5;
Abstract
Pharmacogenetics (also see pharmacogenetics data for specific ARVs)
       
     Journal Papers, Abstracts, and Commentaries
 
 
Pharmacogenetics of antiretrovirals.
Tozzi V.
 Antiviral Res. 2009 Sep 7
 Abstract

HIV Pharmacogenetics in Clinical Practice: Recent Achievements and Future Challenges.
Tozzi V, Libertone R, Liuzzi G.,et al
Curr HIV Res. 2008 Nov;6(6):544-54.
Abstract

Selecting anti-HIV therapies based on a variety of genomic and clinical factors.
Rosen-Zvi M, Altmann A, Prosperi M, et al
 Bioinformatics. 2008 Jul 1;24(13):i399-406
 Abstract
 
Pharmacogenomics of antiretrovirals.
Roca B.
 Recent Patents Anti-Infect Drug Disc. 2008 Jun;3(2):132-5
 Abstract
 
Hypersensitivity syndrome--the role of pharmacogenetics for prediction of efficacy and safety of
antiretroviral therapy in patients with HIV/AIDS
Cholewińska G.
 Przegl Epidemiol. 2008;62(1):149-54.
Abstract
 
Pharmacogenetics and the potential for the individualization of antiretroviral therapy.
Phillips EJ, Mallal SA.
 Curr Opin Infect Dis. 2008 Feb;21(1):16-24.
 Abstract
 
Host pharmacogenetics in the treatment of HIV and cancer.
Winston A, Hatzimichael E, Marvin V, et al
 Curr Drug Saf. 2006 Jan;1(1):107-16
 Abstract
 
Advances in pharmacogenomics of antiretrovirals: an update.
Ma Q, Brazeau D, Forrest A, Morse GD.
 Pharmacogenomics. 2007 Sep;8(9):1169-78.
 Abstract
 
Pharmacogenetics of anti-HIV drugs.
Telenti A, Zanger UM.
 Annu Rev Pharmacol Toxicol. 2008;48:227-56.
 Abstract
 
PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to
reduce drug adverse events.
Hughes S, Hughes A, Brothers C, et al
 Pharm Stat. 2008 Apr-Jun;7(2):121-9
 Abstract
 
HIV and pharmacogenomics in 2007.
Khoo S.
 Pharmacogenomics. 2007 Jan;8(1):25-7.
 Abstract
 
Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update.
Cressey TR, Lallemant M.
 Infect Genet Evol. 2007 Mar;7(2):333-42.
 Abstract
 
Pharmacogenetics of HIV therapy.
Owen A, Pirmohamed M, Khoo SH, Back DJ.
 Pharmacogenet Genomics. 2006 Oct;16(10):693-703
 Abstract
 
The impact of host pharmacogenetics on antiretroviral drug disposition.
Owen A.
 Curr Infect Dis Rep. 2006 Sep;8(5):401-8.
 Abstract
 
The clinical implications of antiretroviral pharmacogenomics.
Fox J, Boffito M, Winston A.
 Pharmacogenomics. 2006 Jun;7(4):587-96
 Abstract
 
Human genetic variability and HIV treatment response.
 Haas DW.
 Curr HIV/AIDS Rep. 2006 Jul;3(2):53-8
 Abstract
 
Overview of the pharmacogenetics of HIV therapy.
Rodríguez-Nóvoa S, Barreiro P, Jiménez-Nácher I, Soriano V.
 Pharmacogenomics J. 2006 Jul-Aug;6(4):234-45
 Abstract
 
Comparative pharmacogenomics of antiretroviral and cytotoxic treatments.
Stebbing J, Bower M.
 Lancet Oncol. 2006 Jan;7(1):61-8.
Abstract
 
Will pharmacogenomic discoveries improve HIV therapeutics?
Haas DW.
 Top HIV Med. 2005 Aug-Sep;13(3):90-5.
 Abstract
HIV Transmission
 

     Journal Papers, Abstracts, and Commentaries
 
 
Effectiveness of Highly Active Antiretroviral Therapy in Reducing Heterosexual
Transmission of HIV.
Castilla J, Del Romero J, Hernando V, et al 
J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):96-101.
 Abstract
 
Antiretroviral recommendations may influence the rate of transmission of drug-resistant
HIV type 1.
 de Mendoza C, Rodriguez C, Eiros JM 
Clin Infect Dis. 2005 Jul 15;41(2):227-32.
Abstract
 
 
Can Highly Active Antiretroviral Therapy Reduce the Spread of HIV?: A Study
in a Township of South Africa.
 Auvert B, Males S, Puren A,
Acquir Immune Defic Syndr. 2004 Apr 20;36(1):613-621
 Abstract
 
  Decline in HIV infectivity following the introduction of highly active antiretroviral therapy.
Porco TC, Martin JN, Page-Shafer KA, et al
AIDS. 2004 Jan 2;18(1):81-8.
 Abstract
 
  Changes in the transmission dynamics of the HIV epidemic after the wide-scale use
of antiretroviral therapy could explain increases in sexually transmitted infections:
results from mathematical models.
Boily MC, Bastos FI, Desai K, Masse B.
Sex Transm Dis. 2004 Feb;31(2):100-13
 Abstract 
 

HIV Main Page Main New/Newsworthy     Home Page    

HAART/ARVs Main Page